Roivant Sciences (NASDAQ:ROIV) CEO Sells $6,990,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Monday, July 27th. The shares were sold at an average price of $34.95, for a total value of $6,990,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $56,376,551.85. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Eric Venker also recently made the following trade(s):

• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00.
• On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00.

Roivant Sciences Stock Down 1.8%

ROIV stock opened at $33.91 on Friday. The firm has a market capitalization of $24.39 billion, a PE ratio of -56.52 and a beta of 1.11. Roivant Sciences Ltd. has a twelve month low of $10.90 and a twelve month high of $37.00. The stock has a 50-day simple moving average of $32.63 and a two-hundred day simple moving average of $29.05.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ROIV shares. Guggenheim lifted their price target on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. HC Wainwright reiterated a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Citigroup boosted their price target on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Institutional Trading of Roivant Sciences

Several institutional investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. increased its holdings in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP boosted its holdings in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Parallel Advisors LLC boosted its holdings in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares during the period. Kestra Advisory Services LLC bought a new position in Roivant Sciences during the 4th quarter worth approximately $47,000. Finally, Bessemer Group Inc. grew its position in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.